Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 12:02 PM ET
VNDA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $265.13M
- Forward P/E
- 21.93
- EPS (TTM)
- -$4.63
- Dividend yield
- None
- 52-week range
- 4.27 – 9.94
- Day range
- 4.39 – 4.52
- Volume / Avg
- 131.50K / 969.16K
- Beta
- —
- Shares outstanding
- 60.46M
- Next earnings
- Nov 4, 2026
52-week range
VNDA stock today
Shares of Vanda Pharmaceuticals (VNDA) are trading lower on Oct 8 at $4.39, a drop of 3.84% or $0.175 per share, versus the S&P 500's 0.38% decline. Shares are 55.9% below their 52-week high of $9.94, set on Mar 10, 2026 and 2.7% above the 52-week low of $4.27, near the bottom of the past year's range. VNDA is down 48.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 14.3%.
Vanda Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$4.63), so its P/E ratio is not meaningful. Vanda Pharmaceuticals's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Vanda Pharmaceuticals
Company profileVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Mihael H. Polymeropoulos M.D.
- Headquarters
- Washington, DC
- Employees
- 533
- IPO year
- 2006
- Website
- vandapharma.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$11.75+167.96%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.72
Vanda Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LRMRLarimar Therapeutics Inc. | 2.63 | -4.37% | $273.20M | vs VNDA |
| CATXPerspective Therapeutics Inc. | 2.42 | -1.62% | $276.25M | vs VNDA |
| BIOABioAge Labs Inc. | 6.06 | -3.20% | $278.13M | vs VNDA |
| CYPHCypherpunk Technologies Inc. | 2.60 | -14.92% | $279.65M | vs VNDA |
| FULCFulcrum Therapeutics Inc. | 3.70 | +0.84% | $282.38M | vs VNDA |
| BBOTBridgeBio Oncology Therapeutics Inc. | 3.28 | -4.65% | $262.97M | vs VNDA |
| ABEOAbeona Therapeutics Inc. | 4.96 | -2.33% | $283.72M | vs VNDA |
| RCKTRocket Pharmaceuticals Inc. | 2.59 | +1.97% | $283.77M | vs VNDA |
Indexes, lists and sector
Vanda Pharmaceuticals stock FAQ
What is Vanda Pharmaceuticals's stock price today?
VNDA last traded at $4.39 as of Oct 8, 12:02 PM EDT, down 3.84% on the day. Prices are delayed at least 15 minutes.
When is Vanda Pharmaceuticals's next earnings date?
Vanda Pharmaceuticals is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.72.
Who is Vanda Pharmaceuticals's CEO?
Dr. Mihael H. Polymeropoulos M.D. is the chief executive officer of Vanda Pharmaceuticals Inc., which has about 533 employees.
What is the VNDA 52-week high?
The 52-week high for VNDA is $9.94 and the 52-week low is $4.27. The stock is currently 55.9% below its high.